

# Atanasio Pandiella

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4648007/atanasio-pandiella-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217  
papers

9,007  
citations

50  
h-index

85  
g-index

225  
ext. papers

10,025  
ext. citations

6.8  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
217	Membrane-anchored growth factors. <i>Annual Review of Biochemistry</i> , <b>1993</b> , 62, 515-41	29.1	593
216	Sox2 expression in breast tumours and activation in breast cancer stem cells. <i>Oncogene</i> , <b>2012</b> , 31, 1354-65	9.2	383
215	Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. <i>Journal of the National Cancer Institute</i> , <b>1993</b> , 85, 1327-33	9.7	323
214	Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. <i>Molecular Biology of the Cell</i> , <b>2002</b> , 13, 2031-44	3.5	251
213	The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. <i>Cancer Research</i> , <b>2006</b> , 66, 5781-9	10.1	210
212	Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 1726-30	11.5	208
211	Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5546-52	12.9	204
210	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. <i>Blood</i> , <b>2006</b> , 107, 3575-83	2.2	180
209	Neutrophils in cancer: prognostic role and therapeutic strategies. <i>Molecular Cancer</i> , <b>2017</b> , 16, 137	42.1	169
208	Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. <i>Molecular and Cellular Neurosciences</i> , <b>2000</b> , 16, 631-48	4.8	147
207	Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 270-85	4.8	144
206	HER3 overexpression and survival in solid tumors: a meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 266-73	9.7	141
205	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. <i>Molecular and Cellular Biology</i> , <b>2008</b> , 28, 5605-20	4.8	137
204	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , <b>2010</b> , 95, 794-803	6.6	133
203	The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGF alpha into soluble growth factor. <i>Cell</i> , <b>1992</b> , 71, 1157-65	56.2	131
202	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2014</b> , 9, e95219	3.7	119
201	Preclinical development of molecular-targeted agents for cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 8, 200-9	19.4	116

200	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. <i>Leukemia</i> , <b>2009</b> , 23, 1515-27	10.7	113
199	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , <b>2008</b> , 9, 1157-65	21.7	106
198	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , <b>2013</b> , 27, 430-40	10.7	98
197	TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. <i>Journal of Cell Biology</i> , <b>1996</b> , 132, 427-36	7.3	94
196	Genetic abnormalities and patterns of antigenic expression in multiple myeloma. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3661-7	12.9	89
195	EGF raises cytosolic Ca <sup>2+</sup> in A431 and Swiss 3T3 cells by a dual mechanism. Redistribution from intracellular stores and stimulated influx. <i>Experimental Cell Research</i> , <b>1987</b> , 170, 175-85	4.2	86
194	Resistance to Antibody-Drug Conjugates. <i>Cancer Research</i> , <b>2018</b> , 78, 2159-2165	10.1	85
193	Early rise of cytosolic Ca <sup>2+</sup> induced by NGF in PC12 and chromaffin cells. <i>FEBS Letters</i> , <b>1986</b> , 208, 48-51	3.8	82
192	Neuregulins and cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3237-41	12.9	81
191	Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. <i>Cancer Research</i> , <b>2008</b> , 68, 5216-25	10.1	79
190	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. <i>Oncogene</i> , <b>2011</b> , 30, 1059-71	9.2	76
189	Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. <i>PLoS ONE</i> , <b>2009</b> , 4, e5565	3.7	76
188	Omega-conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines. <i>FEBS Letters</i> , <b>1988</b> , 235, 178-82	3.8	74
187	Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. <i>Cancer Research</i> , <b>2017</b> , 77, 4639-4651	10.1	72
186	Multifunctional role of Erk5 in multiple myeloma. <i>Blood</i> , <b>2005</b> , 105, 4492-9	2.2	70
185	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. <i>Oncogene</i> , <b>2014</b> , 33, 148-56	9.2	67
184	Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. <i>Stem Cells</i> , <b>2013</b> , 31, 1075-85	5.8	67
183	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , <b>2009</b> , 113, 3781-91	2.2	66

182	TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. <i>Kidney International</i> , <b>2006</b> , 70, 901-9	9.9	66
181	Autocrine regulation of membrane transforming growth factor-alpha cleavage. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 3279-84	5.4	61
180	Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. <i>Cancer Research</i> , <b>2005</b> , 65, 6801-10	10.1	59
179	Activated release of membrane-anchored TGF-alpha in the absence of cytosol. <i>Journal of Cell Biology</i> , <b>1993</b> , 122, 95-101	7.3	59
178	Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. <i>Cellular Physiology and Biochemistry</i> , <b>2006</b> , 18, 135-42	3.9	58
177	ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. <i>Journal of Immunology</i> , <b>2006</b> , 177, 7607-17	5.3	57
176	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. <i>Biochemical Journal</i> , <b>2000</b> , 346, 359-367	3.8	57
175	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , <b>2012</b> , 26, 1862-9	10.7	54
174	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2543-9	2.2	52
173	Bortezomib is an efficient agent in plasma cell leukemias. <i>International Journal of Cancer</i> , <b>2005</b> , 114, 665-7	7.5	52
172	Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. <i>FEBS Letters</i> , <b>2002</b> , 513, 282-8	3.8	52
171	Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. <i>PLoS ONE</i> , <b>2012</b> , 7, e34914	3.7	51
170	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , <b>2009</b> , 23, 2265-74	10.7	51
169	Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2656-63	2.2	51
168	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , <b>2015</b> , 29, 705-14	10.7	50
167	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , <b>2008</b> , 93, 57-66	6.6	50
166	Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. <i>Journal of Pathology</i> , <b>2006</b> , 208, 108-18	9.4	50
165	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1860-9	10.3	49

164	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. <i>Biochemical Journal</i> , <b>2002</b> , 363, 211-221	3.8	47
163	PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , <b>1986</b> , 137, 343-50	3.4	47
162	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. <i>Gut</i> , <b>2015</b> , 64, 1454-65	19.2	45
161	Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4382-91	12.9	45
160	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. <i>International Journal of Oncology</i> , <b>2012</b> , 41, 1128-38	4.4	43
159	Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 858-68	4.5	43
158	Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. <i>Cellular Physiology and Biochemistry</i> , <b>2004</b> , 14, 301-10	3.9	42
157	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7006-7019	12.9	41
156	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. <i>Scientific Reports</i> , <b>2017</b> , 7, 17530	4.9	41
155	Multisite phosphorylation of Erk5 in mitosis. <i>Journal of Cell Science</i> , <b>2010</b> , 123, 3146-56	5.3	41
154	Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 25933-9	5.4	41
153	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. <i>European Journal of Neuroscience</i> , <b>1999</b> , 11, 1421-30	3.5	41
152	Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1432-46	9.7	39
151	Personalized therapies in the cancer "omics" era. <i>Molecular Cancer</i> , <b>2010</b> , 9, 202	42.1	39
150	Potent antimyeloma activity of a novel ERK5/CDK inhibitor. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2677-87	12.9	38
149	Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1342-52	6.1	38
148	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. <i>BMC Cancer</i> , <b>2014</b> , 14, 302	4.8	37
147	NADPH oxidases as therapeutic targets in chronic myelogenous leukemia. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4014-25	12.9	37

146	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. <i>Biochemical Journal</i> , <b>2002</b> , 363, 211-21	3.8	37
145	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , <b>2014</b> , 5, 8284-305	3.3	37
144	Colorectal cancer and medicinal plants: Principle findings from recent studies. <i>Biomedicine and Pharmacotherapy</i> , <b>2018</b> , 107, 408-423	7.5	36
143	Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 961-70	12.9	36
142	Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. <i>Cellular Signalling</i> , <b>2007</b> , 19, 844-54	4.9	36
141	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. <i>Annals of Oncology</i> , <b>2007</b> , 18, 421-30	10.3	36
140	ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. <i>PLoS ONE</i> , <b>2009</b> , 4, e6124	3.7	35
139	Plasma membrane hyperpolarization and [Ca <sup>2+</sup> ] <sub>i</sub> increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: resemblance to early signals generated by platelet-derived growth factor. <i>Biochemical and Biophysical Research Communications</i> , <b>1989</b> , 163, 1325-31	3.4	35
138	Therapeutic potential of ERK5 targeting in triple negative breast cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 11308-18	3.3	35
137	Targeting the EGF/HER Ligand-Receptor System in Cancer. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 5887-5898	3.5	35
136	Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 244-52	7.5	34
135	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 470-82	4.5	33
134	A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 1387-98	5.9	33
133	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. <i>Oncotarget</i> , <b>2017</b> , 8, 22218-22234	3.3	33
132	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 383	12.8	32
131	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2552-2562	6.1	32
130	Targeting HER receptors in cancer. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 808-17	3.3	32
129	Deficient spindle assembly checkpoint in multiple myeloma. <i>PLoS ONE</i> , <b>2011</b> , 6, e27583	3.7	31

128	ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. <i>Neoplasia</i> , <b>2013</b> , 15, 649-59	6.4	30
127	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	30
126	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , <b>2012</b> , 97, 1110-4	6.6	30
125	Elapachone analogs with enhanced antiproliferative activity. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 53, 264-74	6.8	29
124	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. <i>Oncogene</i> , <b>2017</b> , 36, 1733-1744	9.2	28
123	Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 126, 311-8	4.4	28
122	Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2006</b> , 29, 90-5	2.7	28
121	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 1048-55	14.4	27
120	A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. <i>Journal of Immunological Methods</i> , <b>2002</b> , 264, 77-87	2.5	27
119	BET inhibitors as novel therapeutic agents in breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 71285-71291	3.3	27
118	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. <i>Trends in Cancer</i> , <b>2020</b> , 6, 130-146	12.5	26
117	Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. <i>Haematologica</i> , <b>2008</b> , 93, 851-9	6.6	26
116	Erk5 is activated and acts as a survival factor in mitosis. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1964-72	4.9	26
115	An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	26
114	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 399-406	4	25
113	Tumor-infiltrating lymphocytes in breast cancer: ready for prime time?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1298-9	2.2	25
112	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , <b>2007</b> , 21, 797-804	10.7	25
111	Intracellular calcium homeostasis in a human neuroblastoma cell line: modulation by depolarization, cholinergic receptors, and alpha-latrotoxin. <i>Journal of Neurochemistry</i> , <b>1988</b> , 50, 1708-13 <sup>6</sup>		25

110	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1473-87	4.9	24
109	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154789	3.7	23
108	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , <b>2015</b> , 6, 39538-49	3.3	23
107	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1040	5.3	22
106	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 3403-11	4.3	22
105	The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. <i>Molecular Biology of the Cell</i> , <b>2007</b> , 18, 380-93	3.5	22
104	Protein kinase C-mediated feed back inhibition of the Ca <sup>2+</sup> response at the EGF receptor. <i>Biochemical and Biophysical Research Communications</i> , <b>1987</b> , 149, 145-51	3.4	22
103	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. <i>Oncotarget</i> , <b>2017</b> , 8, 19478-19490	3.3	22
102	Oleic acid blocks epidermal growth factor-activated early intracellular signals without altering the ensuing mitogenic response. <i>Experimental Cell Research</i> , <b>1993</b> , 205, 365-73	4.2	21
101	In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1823-33	6.1	20
100	Molecular pathways: P-Rex in cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4564-9	12.9	20
99	Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. <i>Leukemia Research</i> , <b>2010</b> , 34, 1533-8	2.7	20
98	Alpha 1-adrenergic stimulation of in vitro growth hormone release and cytosolic free Ca <sup>2+</sup> in rat somatotrophs. <i>Endocrinology</i> , <b>1988</b> , 122, 1419-25	4.8	20
97	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175128	3.7	20
96	Proteolysis targeting chimeras (PROTACs) in cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 189	12.8	20
95	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , <b>2017</b> , 8, 73144-73153	3.3	19
94	The evolving landscape of protein kinases in breast cancer: clinical implications. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 68-76	14.4	19
93	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. <i>Biochemical Journal</i> , <b>1999</b> , 344, 339-348	3.8	19



92	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 27923-37	3.3	19
91	HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e11498	12	18
90	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. <i>Biochemical Journal</i> , <b>2000</b> , 346, 359	3.8	18
89	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 15	8.3	18
88	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 693-701	4.4	18
87	Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer. <i>Nutrition and Cancer</i> , <b>2015</b> , 67, 1159-69	2.8	17
86	Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2010</b> , 53, 3835-9	8.3	17
85	N-terminal cleavage of proTGF $\alpha$ occurs at the cell surface by a TACE-independent activity. <i>Biochemical Journal</i> , <b>2005</b> , 389, 161-72	3.8	17
84	In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , <b>2016</b> , 7, 22865-72	3.3	17
83	Antitumoral effect of Ocoxin on acute myeloid leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 6231-42	3.3	17
82	Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. <i>Oncogene</i> , <b>2016</b> , 35, 2756-65	9.2	16
81	Enhancement of antiproliferative activity by molecular simplification of catalpol. <i>Bioorganic and Medicinal Chemistry</i> , <b>2010</b> , 18, 2515-23	3.4	16
80	Novel tyrosine kinase inhibitors in the treatment of cancer. <i>Current Drug Targets</i> , <b>2009</b> , 10, 575-6	3	16
79	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1486	5.3	15
78	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 308	5.3	15
77	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. <i>Oncotarget</i> , <b>2015</b> , 6, 32856-67	3.3	15
76	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 235-46	7.5	14
75	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. <i>Cellular Signalling</i> , <b>2013</b> , 25, 2281-9	4.9	14

74	Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies. <i>Oncotarget</i> , <b>2016</b> , 7, 45042-45051	3.3	14
73	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , <b>2017</b> , 8, 21733-21740	3.3	13
72	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. <i>Oncotarget</i> , <b>2015</b> , 6, 30057-71	3.3	13
71	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2802	8.4	13
70	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>OncImmunology</i> , <b>2019</b> , 8, e1629780	7.2	12
69	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
68	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , <b>2018</b> , 9, 31915-31919	3.3	12
67	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 77, 11-19	14.4	11
66	Do we have to change the way targeted drugs are developed?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e420-1; author reply e422-3	2.2	11
65	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , <b>2011</b> , 96, 687-95	6.6	11
64	Transforming growth factor-alpha. <i>Biochemical Society Transactions</i> , <b>1991</b> , 19, 259-62	5.1	11
63	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 62834-62841	3.3	11
62	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
61	Refining Early Antitumoral Drug Development. <i>Trends in Pharmacological Sciences</i> , <b>2018</b> , 39, 922-925	13.2	11
60	Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. <i>Cancer Medicine</i> , <b>2018</b> , 7, 1896-1907	4.8	10
59	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 200-5	4.3	10
58	Antitumoral effect of Ocoxin in hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2017</b> , 14, 1950-1958	2.6	10
57	TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. <i>Cancer Letters</i> , <b>2019</b> , 453, 34-44	9.9	9

56	Transcriptome evolution from breast epithelial cells to basal-like tumors. <i>Oncotarget</i> , <b>2018</b> , 9, 453-463	3.3	9
55	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , <b>2019</b> , 14, e0209134	3.7	8
54	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 1-8	4.4	8
53	Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer. <i>International Journal of Oncology</i> , <b>2018</b> , 53, 113-123	4.4	8
52	A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. <i>Oncogene</i> , <b>2013</b> , 32, 1452-9	9.2	8
51	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. <i>Biochemical Journal</i> , <b>1999</b> , 344, 339	3.8	8
50	CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 29679-29698	3.3	8
49	Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 504-16	6.1	7
48	Anticancer activity, phytochemical screening and acute toxicity evaluation of an aqueous extract of <i>Aristolochia longa</i> L.. <i>International Journal of Pharmaceutical and Phytopharmacological Research</i> , <b>2017</b> , 6, 20		7
47	Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. <i>Cancer Letters</i> , <b>2020</b> , 470, 161-169	9.9	7
46	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 725-732	4.4	7
45	Modulation of cereblon levels by anti-myeloma agents. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 167-76	1.9	6
44	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , <b>2020</b> , 24, 3117-3127	5.6	6
43	Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. <i>Nanomaterials</i> , <b>2019</b> , 9,	5.4	6
42	A modular approach to trim cellular targets in anticancer drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 6641-5	2.9	6
41	Multisite phosphorylation of P-Rex1 by protein kinase C. <i>Oncotarget</i> , <b>2016</b> , 7, 77937-77949	3.3	6
40	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. <i>Oncotarget</i> , <b>2015</b> , 6, 31272-83	3.3	6
39	Antiproliferative Effect of <i>Synadenium grantii</i> Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester. <i>International Journal of Toxicology</i> , <b>2016</b> , 35, 666-671	2.4	6

38	Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. <i>Molecular Oncology</i> , <b>2017</b> , 11, 1788-1805	7.9	5
37	Mapping Bromodomains in breast cancer and association with clinical outcome. <i>Scientific Reports</i> , <b>2019</b> , 9, 5734	4.9	5
36	Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. <i>Cancer Letters</i> , <b>2020</b> , 491, 50-59	9.9	5
35	MEK5 promotes lung adenocarcinoma. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	5
34	In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer. <i>Cellular Oncology (Dordrecht)</i> , <b>2021</b> , 44, 569-580	7.2	5
33	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
32	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.. <i>Cancers</i> , <b>2021</b> , 14,	6.6	5
31	Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	4
30	The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1061-1076	7.9	4
29	MZ1 co-operates with trastuzumab in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 106	12.8	4
28	Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207776	3.7	4
27	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 78	9.8	4
26	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 337-343	4.5	3
25	Integrin $\beta$ Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , <b>2020</b> , 24, 143-151	4.5	3
24	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 295-307	9.6	3
23	Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 24350-63	5.4	3
22	Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. <i>Journal of Biochemistry</i> , <b>2005</b> , 137, 731-9	3.1	3
21	Screening and Preliminary Biochemical and Biological Studies of [RuCl(-cymene)(-bis(diphenylphosphino)-isopropylamine)][BF] in Breast Cancer Models. <i>ACS Omega</i> , <b>2019</b> , 4, 13005-13014	3.9	2

20	Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease. <i>Journal of Neuroendocrinology</i> , <b>1991</b> , 3, 51-6	3.8	2
19	Phosphoinositide Hydrolysis and Ensuing Calcium and Potassium Fluxes: Role in the Action of EGF and Other Growth Factors. <i>Cellular Physiology and Biochemistry</i> , <b>1992</b> , 2, 196-212	3.9	2
18	Antimyeloma Efficacy of Plitidepsin (Aplidin <sup>®</sup> ): From Bench to the Bedside.. <i>Blood</i> , <b>2007</b> , 110, 1178-1178	2.2	2
17	The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.. <i>Blood</i> , <b>2007</b> , 110, 1515-1515	2.2	2
16	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 763-4	0.8	2
15	Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. <i>Current Cancer Drug Targets</i> , <b>2017</b> , 17, 48-52	2.8	2
14	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 313	12.8	2
13	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 763-764	0.8	2
12	Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA-MB 231 breast cancer cells. <i>Molecular Medicine Reports</i> , <b>2019</b> , 20, 73-80	2.9	2
11	PDCD4 limits prooncogenic neuregulin-ErbB signaling. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 1799-1815	10.3	2
10	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5096-5108	12.9	2
9	Voltage-operated calcium-channel subtypes in human neuroblastoma and rat pheochromocytoma cells. <i>Annals of the New York Academy of Sciences</i> , <b>1989</b> , 560, 249-50	6.5	1
8	Transcriptomic Mapping of Non-Small Cell Lung Cancer p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 786069	8.4	1
7	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5476	6.3	1
6	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 144, 112330	7.5	0
5	Altered proTGF $\beta$ -cleaved TGF $\beta$ ratios offer new therapeutic strategies in renal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 256	12.8	0
4	Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41, 106	12.8	0
3	Achilles' heel of triple negative cancer. <i>Oncoscience</i> , <b>2014</b> , 1, 115-6	0.8	

- 2 Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer..  
*Journal of Clinical Oncology*, **2017**, 35, e17089-e17089 2.2
- 1 Ocoxin oral solution demonstrates antiviral properties in cellular models. *Experimental and  
Therapeutic Medicine*, **2021**, 22, 1127 2.1